Retroperitoneal lymph node dissection in patients with interaortocaval lymph node metastases of transitional cell carcinoma of the urinary tract.
Three patients suffered from renal pelvic, ureteral and bladder cancers that were treated with both standard surgical treatments and two adjuvant cycles of cisplatin-based combination chemotherapy. Metastases of interaortocaval lymph nodes were detected in all patients between 9 and 33 months from the surgery for primary lesions. All patients received three cycles of cisplatin-based combination chemotherapy and retroperitoneal lymph node dissection (RPLND). The chemotherapy achieved partial response (62-98%). Two patients with viable cancer cells died with hepatic metastases; the first 15 months and the second 25 months from the date of diagnosis of distant lymph node metastasis. The third patient, who had no viable cancer cells, remains alive and disease-free 36 months later. Therefore, RPLND after chemotherapy provides prognostic information that helps to define patients who might benefit from additional systemic chemotherapy.
Kim
Chul Jang
CJ
Department of Urology, Shiga University of Medical Science, Shiga, Japan. cj-kim@belle.shiga-med.ac.jp
Wakabayashi
Yoshihiko
Y
Kushima
Ryoji
R
Sakano
Yuji
Y
Yoshiki
Tatsuhiro
T
Okada
Yusaku
Y
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D002295:Carcinoma, Transitional Cell / Q000473:pathology* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D012187:Retroperitoneal Space; D014571:Urologic Neoplasms / Q000473:pathology* / Q000628:therapy
D002945:Cisplatin